Leerink Partners has recently raised Aclaris Therapeutics Inc (ACRS) stock to Outperform rating, as announced on Today, according to Finviz. Earlier, on Today, Jefferies had raised the stock from a ...

Natural Alternatives International Inc (NAII) is expected to report for 1Q. New Concept Energy Inc (GBR) is expected to report for 3Q. Nuvei Corp (NVEI.T) is expected to report $0.17 for 3Q. Phio ...

▲点击上方的蓝色“医谷”关注我们日前，博奥信生物宣布与Aclaris ...

- 博奥信将获得超过4000万美元的现金付款，作为首付款以及承担部分开发成本和药物产品材料费用，同时博奥信还将获得 Aclaris Therapeutics 19.9% ...

Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets: Newark, Delaware Wednesday, November 20, ...

根据协议条款，博奥信将获得超过4000万美元的现金付款，作为首付款以及承担部分开发成本和药物产品材料费用。博奥信还将获得Aclaris Therapeutics ...

Traders rushed to scoop up shares of Aclaris Therapeutics Inc. (Nasdaq:ACRS), pushing the price of this small cap to close up ...

A %Healthcare company based out of Pennsylvania caused quite the stir on Tuesday after the company announced that it had ...

On Monday, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) entered into an exclusive license agreement with Biosion Inc for ...

Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...

周二，Aclaris Therapeutics (NASDAQ: ACRS)宣布与Biosion达成重要的许可协议，获得两种潜在炎症治疗药物的全球权利（不包括中国）。这些许可的化合物包括BSI-045B（也称为TQC2731，一种抗TSLP单克隆抗体）和BSI-502（一种抗TSLP加抗IL4R双特异性抗体），两者都旨在治疗特应性皮炎和其他炎症性疾病。 公告详细介绍了Aclaris分享的BSI-0 ...

In a report released yesterday, Christopher Raymond from Piper Sandler upgraded Aclaris Therapeutics (ACRS – Research Report) to a Buy, with a ...